Similar Search Results

Spurious correlation in estimation of the health production function: A note

Akkoyunlu, Sule; Lichtenberg, Frank R.; Siliverstovs, Boriss - 2009

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …

Persistent link: https://www.econbiz.de/10010285825

The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003-2013

Lichtenberg, Frank R. - In: Latin American Economic Review 26 (2017) 1, pp. 1-22

I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003-2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger …

Persistent link: https://www.econbiz.de/10011994326

Spurious correlation in estimation of the health production function: A note

Akkoyunlu, Sule; Lichtenberg, Frank R.; Siliverstovs, Boriss - 2009

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …

Persistent link: https://www.econbiz.de/10010315553

The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996-2019

Lichtenberg, Frank R. - In: Swiss Journal of Economics and Statistics 158 (2022) 1, pp. 1-24

We analyze the association that pharmaceutical innovation had with premature mortality from all diseases in Switzerland … 2002-2019. The analysis is performed by investigating whether the diseases that experienced more pharmaceutical innovation … had larger subsequent declines in premature mortality and hospitalization. Pharmaceutical innovation is measured by the …

Persistent link: https://www.econbiz.de/10013205824

Are patients more adherent to newer drugs?

Blankart, Katharina E.; Lichtenberg, Frank R. - In: Health Care Management Science 23 (2020) 4, pp. 605-618

The annual preventable cost from non-adherence in the US health care system amounts to $100 billion. While the relationship between adherence and the health system, the condition, patient characteristics and socioeconomic factors are established, the role of the heterogeneous productivity of...

Persistent link: https://www.econbiz.de/10014503918